List All Multiple Myeloma Trials

Multiple Myeloma

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Status Conditions Phase Study ID
Recruiting Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Phase I 2450

This phase I trial is studying the side effects and best dose of yttrium Y 90 anti-CD45 monoclonal antibody BC8 when given together with fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant in treating patients with multiple myeloma. Radiolabeled monoclonal antibodies, such as yttrium Y 90 anti-CD45 monoclonal antibody BC8, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving chemotherapy drugs, such as fludarabine phosphate, and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving yttrium Y 90 anti-CD45 monoclonal antibody BC8, fludarabine phosphate, and total-body irradiation before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening and may be an effective treatment for multiple myeloma.

Damian J. Green
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Patients must have symptomatic myeloma requiring treatment (defined as significant anemia [hemoglobin (HgB) less than 10 gm/dl], renal dysfunction [creatinine greater than 2.0] not attributable to other causes, lytic bone disease on x-rays, or hypercalcemia) and meet one of the following requirements:

    • Have at least 1 high risk feature at diagnosis (including deletion 13 or hypodiploidy by conventional cytogenetics, t(4;14), t(14;16) or deletion 17 by fluorescence in situ hybridization [FISH], beta 2 microglobulin greater than 3.5, lactate dehydrogenase [LDH] greater than 1.5 x upper limit of normal [ULN]); OR
    • Have progressive disease on primary therapy with or without prior autologous stem cell transplant; OR
    • Have progressive disease following autologous transplant; it is acceptable for these patients to have a second transplant for disease reduction
  • Bone marrow cellularity of at least 50 percent of normal by core biopsy
  • Eastern Cooperative Oncology Group (ECOG) less than or equal to 2
  • Measured creatinine clearance greater than 50 ml/min or estimated creatinine clearance greater than 50 ml/min
  • For females of childbearing potential, must have a negative pregnancy test
  • Patients must have an human leukocyte antigen (HLA)-identical sibling donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and or National Marrow Donor Program (NMDP) criteria for peripheral blood stem cell (PBSC) donation, as follows:

    • Sibling donor: A patient and sibling donor should be matched for HLA-A, B, C, DRB1 and DQB1 by an intermediate resolution deoxyribonucleic acid (DNA)-based method
    • Unrelated donor: An unrelated donor and recipient should be typed by a high resolution DNA-based method, and ideally matched for HLA-A, B, C, DRB1 and DQB1 alleles, or if there is only a single locus disparity mismatched for an HLA-DQB1 antigen or allele; an unrelated donor may also be mismatched for any single 1) one HLA-A, B or C antigen or allele, or 2) HLA-DRB1 allele (with or without matching for HLA-DQB1)
  • Ability to provide informed consent
  • DONOR: Patients must have an HLA matched donor as well as standard SCCA and or NMDP criteria for PBSC donation; donors must consent and be eligible to undergo GCSF mobilization and PBSC harvest; marrow is not allowed as a source of stem cells on this study
Exclusions (conditions that would prevent participation in this study)
  • Patients with the following organ dysfunction:

    • Left ventricular ejection fraction less than 35 percent
    • Corrected diffusion capacity of carbon monoxide (DLCO) less than 35 percent or receiving supplemental continuous oxygen
    • Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidences by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease
  • Pregnant or breast-feeding females
  • Circulating antibody against mouse immunoglobulin (HAMA)
  • Prior allogeneic transplant
  • Plasmacytomas greater than 1cm in marrow areas measured by magnetic resonance imaging (MRI) or extramedullary plasmacytomas; patients may receive cytoreductive therapy, including allogeneic stem cell transplant (ASCT) (if high risk) or second ASCT (if failed a prior ASCT) to achieve disease control
  • Prior radiation to maximally tolerated levels to any critical normal organ, or greater than 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)
  • Patients who are known to be seropositive for human immunodeficiency virus (HIV)
  • Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
Last Updated
October 14, 2015
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.